Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics, Inc.

Unicycive is focused on delivering disease-modifying therapies for major global health issues, particularly in relation to kidney diseases.

COM:UNICYCIVE

Unicycive

Last Close

0.53

22/11 21:00

Market Cap

41.21M

Beta: -

Volume Today

841.15K

Avg: -